PMID- 35237271
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220531
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Role of HLA-G in Viral Infections.
PG  - 826074
LID - 10.3389/fimmu.2022.826074 [doi]
LID - 826074
AB  - The human leukocyte antigen (HLA)-G is a non-classical HLA class I molecule, 
      which has distinct features to classical HLA-A, -B, -C antigens, such as a low 
      polymorphism, different splice variants, highly restricted, tightly regulated 
      expression and immune modulatory properties. HLA-G expression in tumor cells and 
      virus-infected cells, as well as the release of soluble HLA-G leads to escape 
      from host immune surveillance. Increased knowledge of the link between HLA-G 
      expression, viral infection and disease progression is urgently required, which 
      highlights the possible use of HLA-G as novel diagnostic and prognostic biomarker 
      for viral infections, but also as therapeutic target. Therefore, this review aims 
      to summarize the expression, regulation, function and impact of HLA-G in the 
      context of different viral infections including virus-associated cancers. The 
      characterization of HLA-G-driven immune escape mechanisms involved in the 
      interactions between host cells and viruses might result in the design of novel 
      immunotherapeutic strategies targeting HLA-G and/or its interaction with its 
      receptors on immune effector cells.
CI  - Copyright (c) 2022 Jasinski-Bergner, Schmiedel, Mandelboim and Seliger.
FAU - Jasinski-Bergner, Simon
AU  - Jasinski-Bergner S
AD  - Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle 
      (Saale), Germany.
FAU - Schmiedel, Dominik
AU  - Schmiedel D
AD  - Department of Good Manufacturing Practice (GMP) Development & Advanced Therapy 
      Medicinal Products (ATMP) Design, Fraunhofer Institute for Cell Therapy and 
      Immunology (IZI), Leipzig, Germany.
FAU - Mandelboim, Ofer
AU  - Mandelboim O
AD  - The Lautenberg Center for General and Tumor Immunology, The BioMedical Research 
      Institute Israel Canada of the Faculty of Medicine, The Hebrew University 
      Hadassah Medical School, Jerusalem, Israel.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle 
      (Saale), Germany.
AD  - Department of Good Manufacturing Practice (GMP) Development & Advanced Therapy 
      Medicinal Products (ATMP) Design, Fraunhofer Institute for Cell Therapy and 
      Immunology (IZI), Leipzig, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220214
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - HLA-A Antigens
MH  - *HLA-G Antigens/genetics
MH  - Humans
MH  - Immunologic Surveillance
MH  - Polymorphism, Genetic
MH  - *Virus Diseases
PMC - PMC8882596
OTO - NOTNLM
OT  - human leukocyte antigen G
OT  - immune escape
OT  - interleukin 10
OT  - viral infection
OT  - virus-induced tumors
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/04 06:00
MHDA- 2022/05/03 06:00
PMCR- 2022/01/01
CRDT- 2022/03/03 05:35
PHST- 2021/11/30 00:00 [received]
PHST- 2022/01/20 00:00 [accepted]
PHST- 2022/03/03 05:35 [entrez]
PHST- 2022/03/04 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.826074 [doi]
PST - epublish
SO  - Front Immunol. 2022 Feb 14;13:826074. doi: 10.3389/fimmu.2022.826074. eCollection 
      2022.